Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Print   Email Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files. View: All Documents Annnual Reports Corporate Governance Scientific Abstracts Scientific Posters Title Type Size   American Society of Clinical Oncology's Genitourinary Cancers Symposium Antitumor Activity of MDV3100 in Pre- and Post-Docetaxel Advanced Prostate Cancer: Long-Term Follow-Up of the Phase 1–2 Study 329.1 KB ICAD 2010 Annual Meeting Safety and Tolerability for up to 26 Weeks inPatients with Mild-to-Moderate Alzheimer's Disease 205.4 KB American Academy of Neurology (AAN) Annual Meeting Latrepirdine is Well-Tolerated in Patients With Alzheimer's Disease Receiving Memantine or Memantine Plus Donepezil 62.6 KB American Society for Critical Pharmacology and Therapeutics (ASCPT) Lack of a Pharmacokinetic and Pharmacodynamic Interaction between Dimebon (Latrepirdine) and Warfarin in Healthy Subjects 769.1 KB American Society for Critical Pharmacology and Therapeutics (ASCPT) Lack of a Pharmacokinetic Interaction between Dimebon (Latrepirdine) and Digoxin in Healthy Subjects 746.2 KB American Association for Geriatric Psychiatry (AAGP) Latrepirdine is Well-Tolerated in Patients With Alzheimer's Disease Receiving Memantine or Memantine Plus Donepezil March 5-8, 2010 95.3 KB American Academy of Neurology (AAN) Annual Meeting Dimebon (Latrepirdine) Stimulates Neurite Outgrowth and Protects Against Mitochondrial Depolarization in Cultured Hippocampal Neurons 185.2 KB American Academy of Neurology (AAN) Annual Meeting Cognition Enhancement by Dimebon (Latrepirdine) is Not Mediated by Acetylcholinesterase Inhibition or NMDA Receptor Modulation 91.0 KB American Society of Clinical Oncology (ASCO) Annual Meeting Circulating Tumor Cells and Prostate-Specific Antigen as Response Indicator Biomarkers in Chemotherapy-Naive Patients with Progressive Castration-Resistant Prostate Cancer Treated with MDV3100 164.0 KB American Society of Clinical Oncology Genitourinary Cancer Symposium 168.6 KB American Association for Geriatric Psychiatry (AAGP) 95.3 KB 61st American Academy of Neurology (AAN) Annual Meeting Poster Session VI Estimating Disease-Modifying Effects Using a Staggered Start Approach and a Natural History Staggered Start (NHSS) Approach: Preliminary Results From a 12-Month Study of Dimebon and a 6-Month Open-Label Period 69.0 KB 61st American Academy of Neurology (AAN) Annual Meeting Poster Session VIII Dimebon Induces Neurite Outgrowth from Hippocampal, Spinal and Cortical Neurons 82.8 KB American Academy of Neurology (AAN) Annual Meeting 2009 Dimebon Benefits Patient Function and Decreases Caregiver Assistance Time in Alzheimer's Disease: One-Year Clinical Trial Results 427.6 KB ASCO 2009 Genitourinary Cancers Symposium Phase 1-2 Study of MDV3100 in Castration-Resistant Prostate Cancer 373.5 KB Dimebon Induces Neurite Outgrowth and Mitochondrial Stabilization Poster 1.3 MB 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 1.4 MB 2008 AACR Annual Meeting Abstract 18.8 KB AAN abstract for April 17 17.7 KB AAN abstract for April 15 15.9 KB 2007 Annual Report 537.4 KB Stock Option Grant Date Policy 21.4 KB MDV3100 Preclinical Findings-- ASCO Prostate Cancer Symposium 2007 603.9 KB Audit Committee Charter 39.3 KB Code of Conduct and Ethics 46.7 KB Compensation Committee Charter 37.3 KB Nominating and Corporate Governance Committee Charter 42.7 KB Showing 1-27 of 27 Page: 1   = add file to Briefcase